Dr. Reddy’s Laboratories (NSE: DRREDDY) Q2 2025 Earnings Call dated Nov. 05, 2024 Corporate Participants: Richa Periwal — Head of IR M. V. Narasimham — CFO Erez Israeli — CEO Analysts: Kunal Dhamesha — Analyst Neha Manpuria — Analyst Amey Chalke — Analyst Mikaela Franceschina — Analyst Harith Ahamed — Analyst Damayanti Kerai — Analyst […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q3 2025 Earnings Call dated Jan. 23, 2025 Corporate Participants: Richa Periwal — Head, Investor Relations & Corporate Analytics M V Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Kunal Dhamesha — Analyst Neha Manpuria — Analyst Amey Chalke — Analyst Bino Pathiparampil — Analyst Surya […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q4 2025 Earnings Call dated May. 09, 2025 Corporate Participants: Richa Periwal — Head, Corporate Analytics, Corporate Strategy and Investor Relations M V Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Unidentified Speaker Analysts: Neha Manpuria — Analyst Kunal Dhamesha — Analyst Madhav Marda — Analyst Amey […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q1 2026 Earnings Call dated Jul. 23, 2025 Corporate Participants: Aishwarya Sitharam — Investor Relations Richa Periwal — Head of Investor Relations M.V. Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Amey Chalke — Analyst Neha Manpuria — Analyst Damayanti Kerai — Analyst Madhav Marda — […]
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY), the Indian drugmaker, on Wednesday reported a modest rise in third-quarter revenue but a notable decline in net profit as pressure from pricing and product-specific challenges weighed on earnings for the quarter ended Dec. 31, 2025. Revenue Growth Moderates; Profit Falls Consolidated revenue increased 4.4% year-on-year to ₹8,726.8 crore […]
Dr. Reddy’s Laboratories’ latest earnings show a modest rise in profit, but the real story extends far beyond the headline numbers. So, what’s driving this pharmaceutical powerhouse forward? Our latest video analysis breaks down the Q2 FY26 results, uncovering the company’s focus on global generics expansion, cost optimization, and steady progress in biosimilars and specialty segments. […]
Dr. Reddy’s Laboratories Ltd is a leading pharmaceutical company based in India, offering expertise in Active Pharmaceutical Ingredients (APIs), generics, biosimilars, custom pharmaceutical services, and differentiated formulations. Q2 FY26 Earnings Summary Consolidated revenue declined 8.73% year on year to ₹461 crore from ₹503 crore (note: the initial data in the query showed a large figure […]
Company Overview: Dr. Reddy’s Laboratories Ltd is a prominent Indian pharmaceutical company offering a broad range of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Financial Highlights for Q1 FY26: Revenue: ₹8,572 crore, up 11.38% year-on-year from ₹7,696 crore Total Expenses: ₹6,957 crore, up 15.81% year-on-year […]
Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr Reddys Laboratories Ltd reported Revenues for Q4FY25 of ₹8,528.00 Crores up from ₹7,114.00 Crore year on year, a rise of […]
Company Overview: Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy’s Laboratories reported Total revenue for Q4FY25 of ₹ 9,050 Crore up from ₹7,311 Crore in Q4FY24, a […]